Epoprostenol (Prostacyclin)

A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).

Also Known As:

Networked: 4437 relevant articles (284 outcomes, 503 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Sakai, Yoshiki: 16 articles (07/2015 - 12/2005)
2.	Okajima, Kenji: 14 articles (06/2010 - 03/2002)
3.	Barst, Robyn J: 13 articles (02/2015 - 11/2002)
4.	Seeger, W: 12 articles (12/2010 - 03/2000)
5.	Harada, Naoaki: 12 articles (06/2010 - 03/2002)
6.	FitzGerald, Garret A: 11 articles (04/2014 - 03/2002)
7.	Keith, Robert L: 11 articles (02/2013 - 05/2004)
8.	Seeger, Werner: 11 articles (10/2011 - 04/2002)
9.	Narumiya, Shuh: 11 articles (08/2010 - 10/2002)
10.	Sitbon, Olivier: 10 articles (12/2015 - 03/2002)

Related Diseases

1.	Pulmonary Hypertension (Ayerza Syndrome) 06/01/2004 - "We describe a patient whose severe pulmonary hypertension following mitral valve replacement was treated successfully with continuous intravenous epoprostenol." 12/19/2000 - "Prostacyclin has proved to be a beneficial treatment for patients with severe pulmonary hypertension. " 06/01/1995 - "This might be explained by the fact that the reduction of pulmonary vascular resistance during PGI2 amounted to only 65% of the effect of NO. In summary, both inhaled NO and PGI2-aerosol showed beneficial effects on RV performance and may prove helpful in the treatment of acute pulmonary hypertension." 09/01/2010 - "Inhaled prostacyclin has been found to be effective in some patients with pulmonary hypertension. " 07/01/2008 - "Exogenous prostacyclin is effective in reducing pulmonary vascular resistance in some forms of human pulmonary hypertension (PH). "
2.	Ischemia 05/01/1984 - "Prostacyclin may be an effective agent for prevention of ischemia in all areas of the GI tract prone to stress ulceration." 08/01/1986 - "PGI2 ameliorates myocardial injury and reduces functional impairment produced by ischemia in doses that elicit vasodilation. " 02/01/2003 - "Many studies have shown the beneficial effects of prostacyclin in ischemia and reperfusion. " 03/01/1989 - "This study therefore shows that PGI2 at critical low concentrations can depress left ventricular recovery following total ischemia. " 01/01/1989 - "To study this hypothesis, thromboxane and prostacyclin were measured by RIA after incubation of liver tissues removed during and after an ischemia of 90 min in male Wistar rats. "
3.	Thrombosis (Thrombus) 09/01/2015 - "RIAD-Arg11 caused a significant reduction in raft-localized phosphoGPIbβ and diminished the ability of PGI2 to regulate VWF-mediated aggregation and thrombus formation in vitro. " 01/01/1988 - "Efficacy of PGI2 in preventing thrombosis of the extracorporeal circuit was demonstrated in all cases with a dose of 4 ng/kg/min. HF performances remained unaffected whatever antithrombotic agent was used. " 03/21/2002 - "Animal studies show that inhibition of prostacyclin activity does not lead to spontaneous thrombosis but may increase response to thrombotic stimuli. " 01/01/1981 - "The use of prostacyclin in preventing occlusion of microvascular anastomoses by platelet thrombus: an experimental study in rats." 05/01/2014 - "Bdkrb2(-/-) mice are best characterized and they are protected from thrombosis through over expression of components of the renin angiotensin system (RAS) leading to elevated prostacyclin with vascular and platelet inhibition. "
4.	Anoxia (Hypoxia) 07/01/1985 - "Moreover, during hypoxia, associated with the increased PPA and PVR, the administration of PGI2 appears to be particularly effective in "normalizing" these parameters." 10/01/2001 - "Inhaled PGI2 can be useful in the treatment of patients with PHT and severe hypoxia. " 03/01/2000 - "This study was carried out to determine the efficacy of and dose-response relationships to inhaled aerosolized prostacyclin (IAP), when used as a selective pulmonary vasodilator (SPV) in patients with severe hypoxemia due to ARDS. " 12/01/1992 - "The goal of our study was to determine the association of TXA2 and PGI2 levels with hypoxemia in infants born with CDH. " 02/01/2014 - "H2S inhibition of chemical hypoxia-induced proliferation of HPASMCs is mediated by the upregulation of COX-2/PGI2."
5.	Reperfusion Injury 11/25/2002 - "Our study shows that antithrombin did not reduce ischemia/reperfusion injury in the isolated heart, and prostacyclin is not significantly released following antithrombin treatment. " 12/01/2001 - "This study investigates the effects of a prostacyclin analogue (OP-2507) on hepatic ischemia-reperfusion injury. " 10/30/2001 - "Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors." 12/01/1998 - "This study investigated the effects of a prostacyclin analogue (OP-2507) on hepatic ischemia-reperfusion injury. " 11/25/2002 - "We investigated the influence of antithrombin on ischemia/reperfusion injury and prostacyclin release in the isolated rat heart. "

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Iloprost (Ventavis)
3.	Nitric Oxide (Nitrogen Monoxide)
4.	beraprost
5.	Aspirin (Acetylsalicylic Acid)
6.	Idiopathic pulmonary hypertension
7.	Dinoprostone (PGE2)
8.	Thromboxane A2 (A2, Thromboxane)
9.	Alprostadil (Muse)
10.	Vasodilator Agents (Vasodilators)

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Catheters
3.	Warm Ischemia
4.	Liver Transplantation
5.	Artificial Respiration (Mechanical Ventilation)